TISIDB

Summary
Symbol	STX17
Name	syntaxin 17
Aliases	FLJ20651; Syntaxin-17
Chromosomal Location	9q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum membrane Multi-pass membrane protein Smooth endoplasmic reticulum membrane Multi-pass membrane protein Endoplasmic reticulum-Golgi intermediate compartment membrane Multi-pass membrane protein Cytoplasmic vesicle, autophagosome membrane Multi-pass membrane protein Cytoplasmic vesicle, COPII-coated vesicle membrane Multi-pass membrane protein Cytoplasm, cytosol Note=Has a hairpin-like insertion into membranes. Localizes to the completed autophagosome membrane upon cell starvation (PubMed:23217709). May also localize to the mitochondria according to PubMed:23217709.
Domain	-
Function	SNAREs, soluble N-ethylmaleimide-sensitive factor-attachment protein receptors, are essential proteins for fusion of cellular membranes. SNAREs localized on opposing membranes assemble to form a trans-SNARE complex, an extended, parallel four alpha-helical bundle that drives membrane fusion. STX17 is a SNARE of the autophagosome involved in autophagy through the direct control of autophagosome membrane fusion with the lysosome membrane (PubMed:23217709, PubMed:25686604). May also play a role in the early secretory pathway where it may maintain the architecture of the endoplasmic reticulum-Golgi intermediate compartment/ERGIC and Golgi and/or regulate transport between the endoplasmic reticulum, the ERGIC and the Golgi (PubMed:21545355).

> Gene Ontology [ TOP ]
Biological Process	GO:0000045 autophagosome assembly GO:0006888 ER to Golgi vesicle-mediated transport GO:0006906 vesicle fusion GO:0006914 autophagy GO:0007030 Golgi organization GO:0007033 vacuole organization GO:0016050 vesicle organization GO:0016236 macroautophagy GO:0022406 membrane docking GO:0034497 protein localization to pre-autophagosomal structure GO:0044801 single-organism membrane fusion GO:0048193 Golgi vesicle transport GO:0048278 vesicle docking GO:0048284 organelle fusion GO:0061025 membrane fusion GO:0090174 organelle membrane fusion GO:0097111 endoplasmic reticulum-Golgi intermediate compartment organization GO:0097352 autophagosome maturation GO:0097576 vacuole fusion GO:1905037 autophagosome organization
Molecular Function	GO:0000149 SNARE binding GO:0005484 SNAP receptor activity GO:0019902 phosphatase binding GO:0019903 protein phosphatase binding
Cellular Component	GO:0000421 autophagosome membrane GO:0005776 autophagosome GO:0005790 smooth endoplasmic reticulum GO:0005793 endoplasmic reticulum-Golgi intermediate compartment GO:0012507 ER to Golgi transport vesicle membrane GO:0030133 transport vesicle GO:0030134 ER to Golgi transport vesicle GO:0030135 coated vesicle GO:0030658 transport vesicle membrane GO:0030659 cytoplasmic vesicle membrane GO:0030662 coated vesicle membrane GO:0030868 smooth endoplasmic reticulum membrane GO:0030897 HOPS complex GO:0031201 SNARE complex GO:0033116 endoplasmic reticulum-Golgi intermediate compartment membrane GO:0044232 organelle membrane contact site GO:0044233 ER-mitochondrion membrane contact site GO:0097425 smooth endoplasmic reticulum part GO:0099023 tethring complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04130 SNARE interactions in vesicular transport hsa04140 Regulation of autophagy
Reactome	R-HSA-446203: Asparagine N-linked glycosylation R-HSA-204005: COPII (Coat Protein 2) Mediated Vesicle Transport R-HSA-199977: ER to Golgi Anterograde Transport R-HSA-199991: Membrane Trafficking R-HSA-392499: Metabolism of proteins R-HSA-597592: Post-translational protein modification R-HSA-948021: Transport to the Golgi and subsequent modification R-HSA-5653656: Vesicle-mediated transport

Summary
Symbol	STX17
Name	syntaxin 17
Aliases	FLJ20651; Syntaxin-17
Chromosomal Location	9q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between STX17 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	STX17
Name	syntaxin 17
Aliases	FLJ20651; Syntaxin-17
Chromosomal Location	9q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of STX17 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.51	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	STX17
Name	syntaxin 17
Aliases	FLJ20651; Syntaxin-17
Chromosomal Location	9q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of STX17 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.15	0.486
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.064	0.952
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.21	0.805
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.023	0.938
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.313	0.844
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.345	0.866
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.032	0.921
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.174	0.908
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.121	0.942
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.153	0.872
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.62	0.626
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.034	0.513

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of STX17 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	3.7	0.27
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	3.7	0.314
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	STX17
Name	syntaxin 17
Aliases	FLJ20651; Syntaxin-17
Chromosomal Location	9q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of STX17. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	STX17
Name	syntaxin 17
Aliases	FLJ20651; Syntaxin-17
Chromosomal Location	9q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of STX17. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by STX17. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	STX17
Name	syntaxin 17
Aliases	FLJ20651; Syntaxin-17
Chromosomal Location	9q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of STX17. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	STX17
Name	syntaxin 17
Aliases	FLJ20651; Syntaxin-17
Chromosomal Location	9q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of STX17 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	STX17
Name	syntaxin 17
Aliases	FLJ20651; Syntaxin-17
Chromosomal Location	9q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between STX17 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	STX17
Name	syntaxin 17
Aliases	FLJ20651; Syntaxin-17
Chromosomal Location	9q31.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting STX17 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse STX17